Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-05 in Alzheimer's disease agitation
NCT04947553Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of dextromethorphan + bupropion in Alzheimer's disease (AD), sponsored by Axsome Therapeutics, Inc.. Started Jun 2021; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04947553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947553.